Antiretroviral therapy (ART) for those infected with HIV can prevent onward transmission of infection, but biological efficacy alone is not enough to guide policy decisions about the role of ART in reducing HIV incidence. Epidemiology, economics, demography, statistics, biology, and mathematical modelling will be central in framing key decisions in the optimal use of ART. PLoS Medicine, with the HIV Modelling Consortium, has commissioned a set of articles that examine different aspects of HIV treatment as prevention with a forward-looking research agenda. Interlocking themes across these articles are discussed in this introduction. We hope that this article, and others in the collection, will provide a foundation upon which greater collaborations between disciplines will be formed, and will afford deeper insights into the key factors involved, to help strengthen the support for evidence-based decision-making in HIV prevention.

Additional Metadata
Contributor The HIV Modelling Consortium Treatment as Prevention Editorial Writing Group
Sponsor The HIV Modelling Consortium is funded by the Bill & Melinda Gates Foundation through a grant to Imperial College London.
Persistent URL dx.doi.org/10.1371/journal.pmed.1001259, hdl.handle.net/1765/102586
Journal PLoS Medicine
Citation
Bärnighausen, T, Becker, S. (Stephen), Bendavid, A, Bershteyn, A, Blandford, J, Boily, M-C, … Zaba, B. (2012). Hiv treatment as prevention: Models, data, and questions-towards evidence-based decision-making. PLoS Medicine, 9(7). doi:10.1371/journal.pmed.1001259